To the Editor: The clinical review by Dr Dalakas1 underscores that intravenous immunoglobulin (IVIG)
is the treatment of choice in Guillain-Barré syndrome (GBS), multifocal
motor neuropathy, and chronic inflammatory demyelinating polyneuropathy (CIDP)
and that it is useful instead of plasma exchange for management of myasthenia
gravis. On the other hand, he stresses the necessity of further studies of
dose-finding effects, pharmacoeconomics, and quality of life (QOL) assessments
to improve the evidence base for clinical practice.
Padua L, Aprile I, Caliandro P, Pazzaglia C, Tonali P. Intravenous Immunoglobulin and Quality of Life. JAMA. 2004;292(12):1429–1430. doi:10.1001/jama.292.12.1429-a